dopamine progenitor cell replacement

Class

immune-evasive iPSC-derived cell therapy

Dopamine progenitor cell replacement is a regenerative approach to Parkinson's disease, a neurodegenerative disorder marked by progressive loss of dopamine-producing neurons in a midbrain region called the substantia nigra. These neurons send projections to the striatum, where dopamine release governs the initiation and smoothness of movement; their loss produces tremor, rigidity, and slowness of movement. Rather than supplementing dopamine pharmacologically, this therapy aims to restore the missing cell population itself, using progenitor cells derived from induced pluripotent stem cells (iPSCs) that are directed in culture toward a dopaminergic neuron identity before being implanted into the brain. Because tissue derived from an unrelated donor's iPSCs would ordinarily be recognized as foreign, these cells are engineered to be immune-evasive, reducing the likelihood of rejection and potentially limiting the need for long-term immune suppression. This mechanism applies broadly wherever a defined, identifiable cell population has been lost, but Parkinson's disease is the paradigm case because the dopaminergic deficit is relatively localized and well characterized. Its success depends on transplanted cells surviving, integrating into existing circuitry, and functioning without uncontrolled growth.